The median methylation level of MGMT was significantly higher in glioma patients 64.65% (IQR, 54.87%–74.37%) compared to 38.30% (IQR, 34.13%–45.45%) in healthy controls (P<0.01, Figure 1B). The gene discussed is MGMT; the disease is central nervous system cancer.